Handel Ionis Pharmaceuticals, Inc. - IONS CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.17 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.025457% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.003235% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Ionis Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Nøglestatistikker
| Tidligere luk* | 42.94 |
| Åben* | 42.97 |
| 1-Års Ændring* | 19.76% |
| Dagens Spænd* | 41.13 - 42.97 |
| 52-Ugers Spænd | 32.69-48.82 |
| Gennemsnitlig Volumen (10 dage) | 1.48M |
| Gennemsnitlig Volumen (3 måneder) | 21.22M |
| Market Cap | 5.97B |
| P/E-forhold | -100.00K |
| Udestående aktier | 143.09M |
| Omsætning | 575.97M |
| EPS | -2.31 |
| Dividend (Udbytte %) | N/A |
| Beta | 0.52 |
| Næste indtjeningsopgørelse | Aug 7, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 41.71 | 0.52 | 1.26% | 41.19 | 43.27 | 41.08 |
| Jun 1, 2023 | 42.94 | 3.49 | 8.85% | 39.45 | 43.03 | 39.45 |
| May 31, 2023 | 40.73 | 0.71 | 1.77% | 40.02 | 41.21 | 39.74 |
| May 30, 2023 | 40.51 | 0.26 | 0.65% | 40.25 | 41.55 | 39.84 |
| May 26, 2023 | 40.60 | 2.27 | 5.92% | 38.33 | 40.83 | 38.33 |
| May 25, 2023 | 39.13 | -0.39 | -0.99% | 39.52 | 41.57 | 38.89 |
| May 24, 2023 | 41.24 | -0.58 | -1.39% | 41.82 | 42.47 | 41.09 |
| May 23, 2023 | 42.16 | 1.62 | 4.00% | 40.54 | 43.42 | 40.54 |
| May 22, 2023 | 40.61 | 1.75 | 4.50% | 38.86 | 40.81 | 37.78 |
| May 19, 2023 | 39.02 | 3.61 | 10.19% | 35.41 | 39.31 | 35.41 |
| May 18, 2023 | 36.58 | 2.03 | 5.88% | 34.55 | 36.70 | 34.55 |
| May 17, 2023 | 36.13 | 1.42 | 4.09% | 34.71 | 36.29 | 34.70 |
| May 16, 2023 | 35.79 | 0.93 | 2.67% | 34.86 | 35.96 | 34.81 |
| May 15, 2023 | 36.09 | 0.68 | 1.92% | 35.41 | 36.39 | 34.70 |
| May 12, 2023 | 35.38 | 0.05 | 0.14% | 35.33 | 35.68 | 35.16 |
| May 11, 2023 | 35.48 | 0.79 | 2.28% | 34.69 | 35.72 | 34.69 |
| May 10, 2023 | 35.69 | 0.86 | 2.47% | 34.83 | 36.65 | 34.83 |
| May 9, 2023 | 35.57 | 0.81 | 2.33% | 34.76 | 36.18 | 34.51 |
| May 8, 2023 | 35.18 | -0.28 | -0.79% | 35.46 | 35.88 | 34.81 |
| May 5, 2023 | 36.06 | 0.94 | 2.68% | 35.12 | 36.55 | 34.80 |
Ionis Pharmaceuticals, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| Monday, June 12, 2023 | ||
| Tid (UTC) (UTC) 16:20 | Land US
| Begivenhed Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tid (UTC) (UTC) 12:30 | Land US
| Begivenhed Q2 2023 Ionis Pharmaceuticals Inc Earnings Release Q2 2023 Ionis Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Tuesday, November 7, 2023 | ||
| Tid (UTC) (UTC) 13:30 | Land US
| Begivenhed Q3 2023 Ionis Pharmaceuticals Inc Earnings Release Q3 2023 Ionis Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total omsætning | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
| Omsætning | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
| Kost af omsætning, Total | 14.116 | 10.842 | 11.947 | 4.384 | 1.82 |
| Bruttofortjeneste | 573.251 | 799.614 | 717.317 | 1118.21 | 597.854 |
| Totale Driftsudgifter | 997.558 | 849.269 | 901.346 | 822.912 | 661.046 |
| Salgs/Generelle/Admin. Udgifter, Total | 150.295 | 170.947 | 332.222 | 286.644 | 244.622 |
| Forskning & Udvikling | 833.147 | 634.953 | 526.877 | 465.688 | 414.604 |
| Usædvanlig Udgift (Indkomst) | 32.527 | 30.3 | 66.196 | 0 | |
| Driftsindtægter | -410.191 | -38.813 | -172.082 | 299.687 | -61.372 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 9.876 | 10.798 | 37.592 | 39.765 | -14.602 |
| Andre, Netto | -7.274 | -1.133 | -0.062 | -0.686 | -0.182 |
| Netto Indkomst Før Skat | -257.985 | -29.148 | -134.552 | 338.766 | -76.156 |
| Netto Indkomst Efter Skat | -269.722 | -28.597 | -479.743 | 287.259 | -117.115 |
| Minoritetsrente | 0 | 0 | 35.48 | -9.116 | 58.756 |
| Netto Indkomst Før Ekstra Ting | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
| Netto Indkomst | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
| Fortyndelsesændring | 0 | ||||
| Fortyndet Netto Indkomst | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
| Fortyndet Vægtet Gennemsnit Aktier | 141.848 | 141.021 | 139.612 | 153.164 | 134.056 |
| Fortyndet EPS Uden Ekstraordinære Ting | -1.90149 | -0.20279 | -3.18213 | 1.81598 | -0.43533 |
| Fortyndet Normaliseret EPS | -2.58703 | -0.05286 | -3.04106 | 2.18246 | -0.43533 |
| Totale Ekstraordinære Ting | 332.1 | ||||
| Gain (Loss) on Sale of Assets | 149.604 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 130.524 | 151.889 | 159.767 | 133.791 | 141.919 |
| Omsætning | 130.524 | 151.889 | 159.767 | 133.791 | 141.919 |
| Kost af omsætning, Total | 1.343 | 3.686 | 1.515 | 4.745 | 4.17 |
| Bruttofortjeneste | 129.181 | 148.203 | 158.252 | 129.046 | 137.749 |
| Totale Driftsudgifter | 244.672 | 359.908 | 218.921 | 219.305 | 199.423 |
| Salgs/Generelle/Admin. Udgifter, Total | 45.516 | 47.95 | 34.416 | 33.802 | 34.127 |
| Forskning & Udvikling | 197.813 | 308.272 | 182.99 | 180.758 | 161.126 |
| Driftsindtægter | -114.148 | -208.019 | -59.154 | -85.514 | -57.504 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 16.49 | 13.436 | 7.732 | -5.064 | -6.754 |
| Andre, Netto | -15.285 | 0.649 | 4.713 | -12.297 | 0.187 |
| Netto Indkomst Før Skat | -112.943 | -44.33 | -46.709 | -102.875 | -64.071 |
| Netto Indkomst Efter Skat | -124.323 | -52.43 | -46.992 | -105.135 | -65.165 |
| Minoritetsrente | 0 | ||||
| Netto Indkomst Før Ekstra Ting | -124.323 | -52.43 | -46.992 | -105.135 | -65.165 |
| Netto Indkomst | -124.323 | -52.43 | -46.992 | -105.135 | -65.165 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -124.323 | -52.43 | -46.992 | -105.135 | -65.165 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -124.323 | -52.43 | -46.992 | -105.135 | -65.165 |
| Fortyndet Netto Indkomst | -124.323 | -52.43 | -46.992 | -105.135 | -65.165 |
| Fortyndet Vægtet Gennemsnit Aktier | 142.735 | 142.046 | 141.95 | 141.794 | 141.599 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.87101 | -0.36911 | -0.33105 | -0.74146 | -0.46021 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.87101 | -1.05369 | -0.33105 | -0.74146 | -0.46021 |
| Usædvanlig Udgift (Indkomst) | |||||
| Gain (Loss) on Sale of Assets | 149.604 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 2202.69 | 2345.05 | 2130.71 | 2720.6 | 2207.89 |
| Likvider og Kortsigtede Investeringer | 1986.87 | 2114.97 | 1892.38 | 2499.54 | 2084.07 |
| Likvider & Lignende | 276.472 | 869.191 | 397.664 | 683.287 | 278.82 |
| Kortsigtede Investeringer | 1710.4 | 1245.78 | 1494.71 | 1816.26 | 1805.25 |
| Totale Tilgodehavender, Netto | 25.538 | 61.896 | 76.204 | 63.034 | 12.759 |
| Accounts Receivable - Trade, Net | 25.538 | 61.896 | 76.204 | 63.034 | 12.759 |
| Total Inventory | 22.033 | 24.806 | 21.965 | 18.18 | 8.582 |
| Other Current Assets, Total | 168.254 | 143.374 | 140.163 | 139.839 | 102.473 |
| Total Assets | 2533.88 | 2611.69 | 2389.75 | 3233.11 | 2667.78 |
| Property/Plant/Equipment, Total - Net | 255.838 | 196.069 | 181.077 | 166.251 | 132.16 |
| Property/Plant/Equipment, Total - Gross | 343.554 | 298.722 | 240.264 | 193.634 | |
| Accumulated Depreciation, Total | -87.716 | -102.653 | -74.013 | -61.474 | |
| Intangibles, Net | 29.005 | 27.937 | 25.674 | 24.032 | |
| Other Long Term Assets, Total | 75.344 | 41.567 | 50.034 | 320.59 | 303.706 |
| Total Current Liabilities | 311.561 | 240.55 | 598.898 | 273.005 | 280.294 |
| Accounts Payable | 17.921 | 11.904 | 17.199 | 16.067 | 28.66 |
| Accrued Expenses | 196.494 | 129.97 | 155.889 | 106.152 | 77.629 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.32 | 0.926 | 316.11 | 13.749 | |
| Other Current Liabilities, Total | 96.826 | 97.75 | 109.7 | 150.786 | 160.256 |
| Total Liabilities | 1960.99 | 1839.95 | 1646.47 | 1762.02 | 1619.7 |
| Total Long Term Debt | 1182.72 | 1228.02 | 623.529 | 770.3 | 632.971 |
| Long Term Debt | 1182.72 | 1228.02 | 623.529 | 770.3 | 632.971 |
| Capital Lease Obligations | |||||
| Other Liabilities, Total | 466.709 | 371.379 | 424.046 | 505.26 | 567.359 |
| Total Equity | 572.887 | 771.737 | 743.282 | 1471.09 | 1048.08 |
| Common Stock | 0.142 | 0.141 | 0.14 | 0.14 | 0.138 |
| Additional Paid-In Capital | 2059.85 | 1964.17 | 1895.52 | 2203.78 | 2047.25 |
| Retained Earnings (Accumulated Deficit) | -1429.62 | -1159.9 | -1131.31 | -707.534 | -967.293 |
| Other Equity, Total | -57.48 | -32.668 | -21.071 | -25.29 | -32.016 |
| Total Liabilities & Shareholders’ Equity | 2533.88 | 2611.69 | 2389.75 | 3233.11 | 2667.78 |
| Total Common Shares Outstanding | 142.058 | 141.21 | 140.366 | 140.34 | 137.929 |
| Minority Interest | 213.453 | 139.081 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 2542.62 | 2202.69 | 2152.13 | 2191.15 | 2253.12 |
| Likvider og Kortsigtede Investeringer | 2346.78 | 1986.87 | 1981.66 | 2021.83 | 2052.39 |
| Likvider & Lignende | 309.031 | 276.472 | 314.993 | 521.917 | 542.513 |
| Kortsigtede Investeringer | 2037.75 | 1710.4 | 1666.67 | 1499.91 | 1509.88 |
| Totale Tilgodehavender, Netto | 13.914 | 25.538 | 6.645 | 6.751 | 26.122 |
| Accounts Receivable - Trade, Net | 13.914 | 25.538 | 6.645 | 6.751 | 26.122 |
| Total Inventory | 22.2 | 22.033 | 20.645 | 19.811 | 24.032 |
| Other Current Assets, Total | 159.724 | 168.254 | 143.173 | 142.759 | 150.577 |
| Total Assets | 2885.22 | 2533.88 | 2421.97 | 2456.13 | 2519.09 |
| Property/Plant/Equipment, Total - Net | 264.306 | 255.838 | 180.806 | 177.015 | 177.724 |
| Intangibles, Net | 29.605 | 29.054 | 29.295 | ||
| Other Long Term Assets, Total | 78.296 | 75.344 | 59.434 | 58.916 | 58.949 |
| Total Current Liabilities | 259.221 | 311.561 | 283.454 | 267.811 | 228.45 |
| Accounts Payable | 10.499 | 17.921 | 20.545 | 10.351 | 16.125 |
| Accrued Expenses | 130.862 | 189.279 | 158.412 | 159.321 | 115.781 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 8.239 | 7.535 | 4.97 | 4.732 | 4.206 |
| Other Current Liabilities, Total | 109.621 | 96.826 | 99.527 | 93.407 | 92.338 |
| Total Liabilities | 2398.65 | 1960.99 | 1827.61 | 1831.41 | 1809.52 |
| Total Long Term Debt | 1184.38 | 1182.72 | 1249.5 | 1248.4 | 1247.93 |
| Long Term Debt | 1184.38 | 1182.72 | 1249.5 | 1248.4 | 1247.93 |
| Other Liabilities, Total | 955.054 | 466.709 | 294.656 | 315.196 | 333.138 |
| Total Equity | 486.57 | 572.887 | 594.361 | 624.726 | 709.574 |
| Common Stock | 0.143 | 0.142 | 0.142 | 0.142 | 0.142 |
| Additional Paid-In Capital | 2089.36 | 2059.85 | 2034.55 | 2008.79 | 1983.08 |
| Retained Earnings (Accumulated Deficit) | -1553.95 | -1429.62 | -1377.19 | -1330.2 | -1225.07 |
| Other Equity, Total | -48.983 | -57.48 | -63.14 | -54.007 | -48.578 |
| Total Liabilities & Shareholders’ Equity | 2885.22 | 2533.88 | 2421.97 | 2456.13 | 2519.09 |
| Total Common Shares Outstanding | 143.023 | 142.058 | 142.017 | 141.831 | 141.753 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -269.722 | -28.597 | -479.743 | 287.259 | 214.985 |
| Likvider Fra Driftsaktiviteter | -274.37 | 30.799 | 35.892 | 345.627 | 602.906 |
| Likvider Fra Driftsaktiviteter | 14.328 | 15.487 | 13.365 | 12.54 | 10.706 |
| Amortization | 2.415 | 2.352 | 2.064 | 1.912 | 1.822 |
| Deferred Taxes | 0 | 0 | 341.729 | 0.911 | -290.516 |
| Ikke-Likvide Ting | -28.962 | 155.375 | 232.032 | 211.806 | 166.484 |
| Likvid Rente Betalt | 2.898 | 4.778 | 6.247 | 9.87 | 9.592 |
| Ændringer i Driftskapital | 7.571 | -113.818 | -73.555 | -168.801 | 499.425 |
| Likvider fra Investeringsaktiviteter | -262.636 | 194.906 | 274.477 | -41.274 | -929.563 |
| Kapitaludgifter | -15.721 | -11.955 | -35.12 | -30.905 | -13.608 |
| Andre Investerings-Cash-Flow-Ting, Total | -246.915 | 206.861 | 309.597 | -10.369 | -915.955 |
| Likvider fra Financieringsaktiviteter | -55.295 | 245.933 | -596.609 | 100.021 | 475.865 |
| Financiering af Cash-Flow-Ting | -10.982 | -168.954 | -558.097 | -138.354 | 0 |
| Udstedelse (Pensionering) af Aktier, Netto | 6.373 | 101.317 | -38.512 | 141.375 | 475.865 |
| Udstedelse (Pensionering) af Gæld, Netto | -50.686 | 313.57 | 0 | 97 | 0 |
| Netto Ændring i Likviditet | -592.719 | 471.527 | -285.623 | 404.467 | 149.19 |
| Cash Taxes Paid | 5.01 | 0.038 | 25.855 | 9.041 | 0 |
| Udenlandsk Børs Effekter | -0.418 | -0.111 | 0.617 | 0.093 | -0.018 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -124.323 | -269.722 | -217.292 | -170.3 | -65.165 |
| Cash From Operating Activities | -133.992 | -274.37 | -74.175 | -49.746 | -31.65 |
| Cash From Operating Activities | 2.604 | 14.328 | 11.301 | 7.484 | 3.701 |
| Amortization | 0.607 | 2.415 | 1.805 | 1.197 | 0.592 |
| Deferred Taxes | 0 | ||||
| Non-Cash Items | 42.124 | -28.962 | 91.563 | 64.125 | 32.983 |
| Cash Taxes Paid | 0.293 | 5.01 | 0.002 | 0.002 | 0.002 |
| Cash Interest Paid | 0.089 | 2.898 | 2.204 | 1.544 | 0.594 |
| Changes in Working Capital | -55.004 | 7.571 | 38.448 | 47.748 | -3.761 |
| Cash From Investing Activities | -325.64 | -262.636 | -474.783 | -290.853 | -287.549 |
| Capital Expenditures | -10.472 | -15.721 | -11.582 | -6.04 | -2.705 |
| Other Investing Cash Flow Items, Total | -315.168 | -246.915 | -463.201 | -284.813 | -284.844 |
| Cash From Financing Activities | 492.087 | -55.295 | -4.276 | -6.11 | -7.325 |
| Financing Cash Flow Items | 489.566 | -10.982 | -10.217 | -9.572 | -9.173 |
| Issuance (Retirement) of Stock, Net | 2.56 | 6.373 | 6.03 | 3.462 | 1.848 |
| Foreign Exchange Effects | 0.104 | -0.418 | -0.964 | -0.565 | -0.154 |
| Net Change in Cash | 32.559 | -592.719 | -554.198 | -347.274 | -326.678 |
| Issuance (Retirement) of Debt, Net | -0.039 | -50.686 | -0.089 | 0 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Fidelity Management & Research Company LLC | Investment Advisor | 14.9808 | 21436334 | 128815 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.7482 | 13948885 | 429096 | 2023-03-31 | LOW |
| T. Rowe Price Investment Management, Inc. | Investment Advisor | 9.1298 | 13064047 | 1385788 | 2023-03-31 | MED |
| Bellevue Asset Management AG | Investment Advisor | 6.6474 | 9511900 | -232000 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.9323 | 7057705 | -70015 | 2023-03-31 | LOW |
| ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 3.7679 | 5391581 | -34061 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.8432 | 4068334 | -150395 | 2023-03-31 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 2.6508 | 3793044 | -359563 | 2023-03-31 | LOW |
| Tweedy, Browne Company LLC | Investment Advisor | 2.4747 | 3541046 | -90 | 2023-03-31 | LOW |
| Deep Track Capital LP | Hedge Fund | 1.9806 | 2834069 | 1628296 | 2023-03-31 | HIGH |
| ARK Investment Management LLC | Investment Advisor | 1.843 | 2637192 | -36346 | 2023-03-31 | LOW |
| BVF Partners L.P. | Hedge Fund | 1.7896 | 2560761 | 1438952 | 2023-03-31 | LOW |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.4847 | 2124500 | 130900 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.4466 | 2069950 | 57227 | 2023-03-31 | LOW |
| Camber Capital Management LP | Hedge Fund | 1.3453 | 1925000 | 0 | 2023-03-31 | MED |
| First Trust Advisors L.P. | Investment Advisor | 1.1454 | 1638943 | -141990 | 2023-03-31 | LOW |
| Macquarie Investment Management | Investment Advisor | 1.044 | 1493903 | 2216 | 2023-03-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9062 | 1296647 | 511086 | 2022-12-31 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.8291 | 1186393 | -69875 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.7778 | 1113042 | 739456 | 2023-03-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group535K+
Handlende
87K+
Månedlkige, aktive klienter
$113M+
Månedlig investeringsvolumen
$64M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Ionis Pharmaceuticals Company profile
Om Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. beskæftiger sig med opdagelse og udvikling af ribonukleinsyre (RNA)-målrettede terapeutika. Selskabet er primært fokuseret på vores kardiovaskulære og neurologiske forretningsområder. Virksomhedens produkter omfatter SPINRAZA, TEGSEDI og WAYLIVRA. SPINRAZA er til behandling af patienter i alle aldre med spinal muskelatrofi (SMA), en progressiv, invaliderende og ofte dødelig genetisk sygdom. TEGSEDI er til behandling af patienter med polyneuropati forårsaget af arvelig transthyretin (TTR), amyloidose (hATTR), en invaliderende, progressiv og dødelig sygdom. WAYLIVRA er et antisense-medicin, der er indiceret som et supplement til diæt hos voksne patienter. Selskabet har over seks lægemidler i fase III-undersøgelser for otte indikationer, som omfatter Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) og Tofersen (SOD1). Dens kardiovaskulære lægemidler under udvikling omfatter Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen og IONIS-AGT-LRx.
| Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com